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Abstract: Amiodarone has emerged as the leading antiarrhythmic therapy for termination and 
prevention of ventricular arrhythmia in different clinical settings because of its proven efficacy 
and safety. In patients with shock refractory out-of-hospital cardiac arrest and hemodynamically 
destabilizing ventricular arrhythmia, amiodarone is the most effective drug available to assist in 
resuscitation. Although the superiority of the transvenous implantable cardioverter defibrillator 
(ICD) over amiodarone has been well established in the preventive treatment of patients at high 
risk of life-threatening ventricular arrhythmias, amiodarone (if used with a beta-blocker) is the 
most effective antiarrhythmic drug to prevent ICD shocks and treat electrical storm. Both the 
pharmacokinetics and the electrophysiologic profile of amiodarone are complex, and its optimal 
and safe use requires careful patient surveillance with respect to potential adverse effects.
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Introduction
Amiodarone was developed originally as an antianginal agent in Belgium (Labaz Inc.) 
in 1962.1 Subsequently its antiarrhythmic abilities were observed;2 early investiga-
tions were primarily confined to Europe and South America where its use as an 
antianginal and antiarrhythmic gained widespread acceptance.3,4 The oral preparation 
(200 mg/tablet) was approved by the Food and Drug Administration (FDA) for use in 
the USA in 1985, and is indicated for adults with life-threatening ventricular arrhyth-
mias when other treatments are ineffective or have not been tolerated. Intravenous 
amiodarone was approved by the FDA in 1995 for the same indication.
Amiodarone is used to manage virtually all forms of supraventricular and ventricular 
tachycardia and has therefore become one of the most frequently used antiarrhythmic 
drugs in clinical practice.5 This review will focus on the role of both the oral and intra-
venous preparation in the treatment and prevention of ventricular tachyarrhythmia.
Pharmacology
Pharmacokinetics
The pharmacokinetics of amiodarone and its metabolites are complex. A basic 
  understanding of the pharmacokinetics is important for the clinician to understand the 
antiarrhythmic properties of both the oral and intravenous preparation.
Amiodarone has a variable (20%–80%) oral bioavailability.6,7 After absorption, 
the drug undergoes extensive enterohepatic circulation. A large first pass effect 
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mono-N-desethyl amiodarone (desethylamiodarone), which 
is active and has similar electrophysiologic effects as the 
parent compound.8 Peak amiodarone serum levels, after oral 
dosing, are achieved within 3–7 hours. The drug can then go 
through many other metabolic pathways to finally undergo 
glucuronidation, which precedes biliary clearance. Renal 
clearance is negligible, thus the dose of the drug does not 
have to be reduced in patients with renal failure, including 
dialysis-dependent patients.
Amiodarone (and desethylamiodarone) is highly lipo-
philic.9 This leads to a large volume of distribution and 
variable uptake into different tissues. A three-compartment 
model best explains the drug’s kinetics. After absorption, 
serum levels in the central or plasma compartment initially 
increase rapidly. After the initial distribution phase, highest 
levels of amiodarone and desethylamiodarone are found in 
the deep compartment, which consists of adipose tissue, 
lung, liver and lymph nodes. Lowest levels are found in 
the peripheral compartment, which is composed of brain, 
muscles and thyroid. Drug levels in the peripheral and deep 
compartments rise at a much lower rate because of the large 
volumes of distribution, accounting for the long loading 
period. This model also explains the different phases of elimi-
nation of amiodarone. After administration of a single dose 
of amiodarone, a wide interpatient variable initial half-life 
is found. This plasma half-life (α phase t1/2α) represents the 
distribution into tissue compartments in which amiodarone 
is sequestered. Elimination from the peripheral and deep 
compartments (terminal elimination) is much slower and 
happens with a linear relationship between the amount of 
drug administered and the steady-state plasma level.7 After 
withdrawal of chronic oral amiodarone therapy, terminal 
elimination half-life (t1/2β) can be up to 60 days.
Data on the clinical usefulness of plasma concentrations 
have been conflicting.8 Some studies have suggested no cor-
relation between the antiarrhythmic effect of amiodarone and 
plasma concentrations. Others have shown that plasma levels 
of 1.0–1.5 mg/L are associated with a decrease in the amount 
of ventricular ectopy, and that levels .2.5 mg/L do not pro-
vide any additional antiarrhythmic benefit. In addition, some 
data suggest that plasma levels .2.5 mg/L are associated with 
increased neurologic adverse reactions, and that higher des-
ethylamiodarone to amiodarone concentration ratios (.1.4) 
are associated with increased risk of toxicity.10
electrophysiology
The electrophysiologic effects of amiodarone are very 
  complex, still incompletely understood and unlike any 
other antiarrhythmic drug. There are important differences 
between the acute and chronic effects of amiodarone on 
cardiac tissue.
Acute amiodarone therapy results in a use-dependent 
inhibition of inward sodium (Vaughan-Williams class I 
effect) and inward calcium currents (Vaughan-Williams 
class IV effect),11 as well as a non-competitive alpha- and 
  beta-blockade effect (Vaughan-Williams class II effect).12 
Acute amiodarone therapy has no consistent effects on the 
repolarization phase of action potentials.11 Clinically these 
effects result in a depressed automaticity of the sinoatrial node 
(SA node) resulting in a decrease in sinus rate, conduction 
slowing and increased refractoriness of the atrioventricular 
(AV) node resulting in depression of AV node function, and 
a stabilizing effect during acute electrical instability. The QT-
interval has been shown to be relatively unaffected by acute 
amiodarone and a prolongation of effective refractory period 
(ERP) in ventricular muscle is minimal or negligible.11,13
The major effect of chronic amiodarone therapy is an 
inhibition of outward potassium currents (Vaughan-Williams 
class III effect) resulting in a prolongation of action potential 
duration (APD), not only in atrial and ventricular muscles but 
also in the SA and AV nodes. This APD prolongation is asso-
ciated with a comparable prolongation of the ERP.11 Unlike 
drugs with “pure” class III effect (eg, d-sotalol, dofetilide), 
the effect of amiodarone on APD and ERP is not reverse-use 
dependent, and the effect is preserved at high heart rates.14
Efficacy
Amiodarone has been shown to be effective for both the 
termination of ongoing ventricular arrhythmia, as well as 
for the prevention of recurrence of ventricular tachycardia/
ventricular fibrillation (VT/VF) during electrical storm or 
after the arrhythmia has subsided.
During VT/VF
The efficacy of amiodarone in the termination of ventricular 
arrhythmias has been tested in different clinical settings.
Two randomized clinical trials have evaluated IV amio-
darone in out-of-hospital cardiac arrest. The Amiodarone 
in Out-of-Hospital Resuscitation of Refractory Sustained 
Ventricular Tachycardia (ARREST) study compared IV 
amiodarone (300 mg) to placebo in a blinded, randomized 
trial in patients with shock-refractory out-of-hospital VF or 
pulseless VT; 44% of amiodarone-treated patients and 34% 
of placebo-treated patients survived to hospital admission 
(P = 0.03).15 The Amiodarone versus Lidocaine in   Prehospital 
Ventricular Fibrillation Evaluation (ALIVE) study compared  Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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amiodarone (5 mg/kg) to lidocaine (1.5 mg/kg) in a blinded, 
randomized trial in patients with out-of-hospital VF, resis-
tant to three shocks, intravenous epinephrine and a further 
shock, or recurrent VF after initial successful defibrillation; 
22.8% of amiodarone-treated patients and 12% of lidocaine-
treated patients survived to hospital admission (P = 0.009).16 
Unadjusted analysis of the latter trial found that, among 
patients whose initial rhythm was VF, the interval from the 
first shock to the administration of the drug was a signifi-
cant predictor of survival (odds ratio [OR] for survival for 
each minute of delay, 0.87; 95% confidence interval [Cl]: 
0.80 to 0.96; P = 0.003).
No placebo-controlled trials have addressed the effective-
ness of amiodarone in terminating hemodynamically tolerated 
monomorphic ventricular tachycardia (mVT). The available 
case series suggest a low termination rate of mVT of 29% 
(95% CI: 0.13 to 0.49)17 and 29% (95% CI: 0.18 to 0.45)18 
to 42% (95% CI: 0.20 to 0.67)19 after administration of 
150 mg and 300 mg IV amiodarone, respectively. All included 
patients had structural heart disease with moderately impaired 
left ventricular ejection fraction (LVEF), mainly secondary 
to ischemic heart disease. In comparison, one randomized, 
unblinded study comparing the efficacy of procainamide 
and lidocaine in terminating mVT in the absence of severe 
congestive heart failure or acute myocardial infarction, 
documented a termination rate of 79% and 19% (P , 0.001), 
respectively.20
The Intravenous Amiodarone Multicenter Investigators 
Group evaluated the effect of intravenous amiodarone in 
hemodynamically destabilizing ventricular arrhythmia refrac-
tory to lidocaine, procainamide and bretylium in hospitalized 
patients with structural heart disease and absence of QT-
prolongation (.0.5 s) or evidence of drug-provocation. Two 
dose-ranging studies were conducted, randomizing patients 
to different dose regimens: 125, 500 or 1000 mg amiodarone 
IV/24 h21 and 500, 1000 or 2000 mg amiodarone IV/24 h,22 
respectively. Supplemental infusions (150 mg) of intravenous 
amiodarone could be given to treat breakthrough ventricular 
arrhythmias. This was allowed to prevent premature study 
termination in the low dose groups, but potentially also 
obscured a differential drug effect at the higher doses with 
respect to recurrent VT/VF event rate (primary endpoint). A 
statistically significant dose-related increase was found in the 
time to first recurrence of arrhythmia between the 125 mg 
and 1000 mg dose group in the first study (median time to 
first event 9.8 hours and 13.7 hours, respectively; P = 0.030) 
and between the 500 mg and the combined 1000 mg and 
2000 mg dose groups over the first 12 hours in the second 
study (4.8 hours and .12 hours, respectively; P = 0.046). 
In both studies the mean number of supplemental infusions 
decreased significantly with increasing blinded amiodarone 
dose, suggestive for a higher efficacy of the higher doses. The 
frequency of amiodarone-related adverse effects was similar 
across all dose groups in both studies.
In a third study by the same group, patients were random-
ized to 125 mg or 1000 mg amiodarone IV/24 h or bretylium 
2500 mg/24 h.23 In this study, high-dose amiodarone was 
more effective than bretylium in preventing arrhythmia 
recurrence (P = 0.087), during hours 0 to 6, when the largest 
number of patients were on blinded therapy. A higher inci-
dence of hypotension was seen in the bretylium group.23
The pattern of VT/VF recurrences suggests that it requires 
12–24 hours for IV amiodarone to reach full efficacy. As a 
result, it seems prudent to expect occasional recurrences 
early after amiodarone is administered; on the other hand, 
recurrences in the first 12–24 hours do not necessarily imply 
that the drug is destined to be ineffective. Due to its sodium-
channel blocking effects, amiodarone also significantly slows 
the rate of VT from its original rate in case of recurrence.
In this latter study, a minority of patients had incessant 
VT (ie, recurrent despite attempted electrical cardioversion). 
Although variation was not significant among the groups, the 
median time from initiation of therapy to termination of inces-
sant VT was as follows: bretylium, 6.98 hours (n = 9), low-dose 
amiodarone, 4.58 hours (n = 13); and high dose amiodarone, 
4.23 hours (n = 12) (P = 0.62). This finding may provide use-
ful information for the treatment of implantable cardioverter 
defibrillator (ICD) patients with electrical storm.
Unmasking of the Brugada ECG pattern type 1 has been 
described after administration of both oral and intravenous 
amiodarone.24,25 Amiodarone should therefore presumably be 
avoided in patients with the Brugada syndrome.
Prevention of VT/VF
Randomized clinical trials have established the superiority 
of the transvenous ICD over antiarrhythmic drugs in the pre-
ventive treatment of patients at high risk of life-threatening 
ventricular arrhythmias, both in primary and secondary 
prevention.26–29 The ICD has therefore become the treatment 
of choice for patients at risk of these arrhythmias.
However, the efficacy of amiodarone in the prevention 
of sudden cardiac death had already been well established 
in the pre-ICD era. A meta-analysis of all randomized 
trials showed that amiodarone reduced total mortality by 
10 to 19%.30 The risk reduction was similar in primary 
prevention after   myocardial infarction or in patients with  Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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congestive heart   failure (CHF), and in secondary prevention 
after cardiac arrest.30 In a pooled database from 2 similar 
randomized clinical trials (the European Amiodarone 
Myocardial Infarction Trial (EMIAT) and the Canadian 
Amiodarone Myocardial Infarction Trial (CAMIAT)), 
that evaluated use of amiodarone in primary prevention 
in patients recovering from myocardial infarction, cardiac 
death and arrhythmic death or resuscitated cardiac arrest, 
were significantly lower in patients receiving amiodarone, 
compared to placebo (P = 0.05 and 0.03, respectively), if 
they were also receiving beta-blockers.31 There appeared 
to be no benefit of amiodarone over placebo in patients not 
receiving   beta-blockers.
In contrast, the Sudden Cardiac Death in Heart Failure 
Trial (SCD-HeFT) showed no survival benefit of treat-
ment with amiodarone over placebo in primary preven-
tion in patients with NYHA class II or III CHF and left 
ventricular ejection fraction (LVEF) #35%, despite a 
high use of beta-blocker (.70%) in both the placebo and 
the amiodarone group.28 The findings were similar for all 
causes of CHF. In the meta-analysis of the ICD secondary 
prevention trials, patients with LVEF .35% appeared to 
obtain little or no survival benefit from the ICD compared 
with amiodarone, whereas those with moderate to severe 
left ventricular dysfunction obtained a significant benefit 
from the ICD.26
In summary, there appears to be no role for amiodarone 
therapy without concomitant ICD in patients with a stable 
chronic low LVEF, both in primary and secondary preven-
tion. In secondary prevention, therapy with amiodarone (if 
used with a beta-blocker) may be a reasonable alternative to 
ICD in selected patients with LVEF .35%, at least in the 
short term.
In ICD recipients amiodarone and ablation therapy may 
play an important role in the reduction of device therapy.
The Optimal Pharmacological Therapy in Cardioverter 
Defibrillator Patients (OPTIC) study was a randomized 
trial that compared amiodarone (200 mg) plus beta-blocker 
with sotalol alone (240 mg, adjusted for renal function) 
or beta-blocker alone (bisoprolol 10 mg or equivalent) in 
412 patients who had received a dual-chamber ICD for 
inducible or spontaneous ventricular tachycardia (VT) or 
ventricular fibrillation (VF) and LVEF #40% or syncope.32 
All ICDs were optimally programmed to avoid shocks (ATP 
up to a rate of 222 bpm; SVT discriminators enabled). 
During one year of follow-up, shocks (appropriate and 
inappropriate) occurred in 41 patients (38.5%) assigned 
to beta-blocker alone, in 26 (24.3%) assigned to sotalol 
alone, and in 12 (10.3%) assigned to amiodarone plus 
beta-blocker.   Amiodarone plus beta-blocker significantly 
reduced the risk of any shock compared with beta-blocker 
alone (HR 0.27; 95% CI: 0.14 to 0.52; P , 0.001) and 
sotalol (HR 0.43; 95% CI: 0.22 to 0.85; P = 0.02). There 
was a trend for sotalol to reduce shocks compared with 
beta-blocker alone (HR 0.61; 95% CI: 0.37 to 1.01; 
P = 0.055). The rates of study drug discontinuation at 1 
year were 18.2% for amiodarone, 23.5% for sotalol, and 
5.3% for beta-blocker alone.
No well-conducted randomized clinical trial has 
been published that compares prophylactic ablation 
with antiarrhythmic drugs for the reduction of device 
therapy in ICD recipients. Two randomized trials have 
compared ICD implant and prophylactic ablation to ICD 
implant alone in secondary prevention in patients with a 
history of myocardial infarction. The SMASH-VT trial 
enrolled patients with a history of VT or VF, not treated 
with antiarrhythmic drugs.33 In that trial, prophylactic 
substrate-based catheter ablation reduced ICD shocks 
from 31% to 9% over a mean follow-up of 22.5 ± 5 
months (P = 0.003), and reduced VT from 33% to 12% 
(P = 0.007). Substantial ablation-related complications 
(pericardial effusion, exacerbation of congestive heart 
failure and deep venous thrombosis) occurred in 5% of 
patients. The 30-day mortality rate was zero after abla-
tion. The VTACH trial enrolled patients with a history of 
stable VT.34 In both the ablation and control groups, 35% 
of patients were treated with amiodarone. In this trial, the 
number of appropriate ICD therapy events per patient and 
per year was also lower in the ablation group than in the 
control group (median 0.2 vs 3.0; P = 0.013). 3.8% of 
patients from the ablation group developed substantial 
ablation-related complications (two ablation procedures 
were terminated prematurely because of transient ischae-
mic ST-segment elevation in one patient and a transient 
cerebral ischaemic event in another). Again, no deaths 
occurred within 30 days after ablation.
Based on the current evidence, we would recommend 
treating all ICD recipients with structural heart disease 
with beta-blockers at the time of ICD implant. If the patient 
develops a recurrence of VT or VF with symptoms or shocks, 
addition of amiodarone, with a maintenance dose of 200 mg 
once daily, to beta-blockers should be considered. Although 
the results of the ablation trials are promising, it is not clear 
whether outcomes of ablation would be similar for non-
ischemic patients or in less experienced centers. At this point, 
ablation is not recommended as a first line treatment. Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Safety and tolerability
Amiodarone has been reported to cause a variety of cardiac 
and extracardiac side effects, both in its oral and intravenous 
formulation (Table 1).
Oral formulation
Of the extracardiac adverse effects, pulmonary fibrosis is the 
most serious since it is potentially fatal. The risk of pulmo-
nary toxicity, as well as hepatic and cutaneous changes, has 
been found to increase with high daily doses over an increased 
length of time (.500 mg/d).35,36 In one study, a higher 
  occurrence of neurological and gastrointestinal side effects 
was associated with amiodarone plasma levels .2.5 mg/L.37 
Corneal microdeposits are found in 76%–100% of patients 
on chronic therapy, but they do not cause permanent eye 
damage.10 Only about 10% of patients experience visual 
disturbances in the form of halos when looking at bright 
lights at night. 10
A meta-analysis of 4 placebo-controlled, randomized tri-
als, involving 1465 patients exposed to a low daily dose of 
amiodarone (152–330 mg/day) for a minimum of 12 months, 
showed significantly higher odds than those on placebo 
(P , 0.05) for experiencing thyroid (OR 4.2, 95% CI: 2.0 
to 8.7), neurologic (OR 2.0, 95% CI: 1.1 to 3.7), skin (OR 
2.5, 95% CI: 1.1 to 6.2)), or bradycardic (OR 2.2, 95% CI: 
1.1 to 4.3) adverse effects.38 A trend toward increased odds 
of pulmonary toxicity was noted (OR 2.0, 95% CI: 0.9 to 
5.3), but this did not reach statistical significance (P = 0.07). 
The unadjusted total incidence of drug discontinuation was 
22.9% in the amiodarone group and 15.4% in the placebo 
group at 1 year of follow-up.
Most adverse effects are reversible with a decrease of amio-
darone maintenance dose or discontinuation of the drug.35–37
The cardiac adverse effects associated with the chronic 
use of amiodarone include sinus bradycardia, high degree 
AV-block and, rarely, torsades de pointes (TdP), a potentially 
life-threatening proarrhythmia. Patients chronically treated 
with amiodarone are at risk of TdP because of the prolon-
gation of repolarization and, therefore, prolongation of 
the QT interval. Among the class III antiarrhytmic drugs, 
amiodarone and azimilide are associated with a lower risk 
for TdP (,1%) than dofetilide and sotalol (3% and 2.5%, 
respectively).39 Several risk factors have been identified for 
the development of TdP, including female gender, baseline 
long QT, concomitant therapy with other QT-prolonging 
agents, hypokalemia and hypomagnesia, bradycardia and 
structural heart disease (including left ventricular hyper-
trophy). Since amiodarone is not renally cleared, renal 
insufficiency is not a risk factor for TdP in patients treated 
with amiodarone, contrary to patients treated with sotalol 
and dofetilide.39 Amiodarone has also been safely used in 
patients with a history of drug-mediated TdP, despite com-
parable prolongation of QTc.40
Amiodarone interacts with the metabolism of many other 
drugs, because of its metabolism through the cytochrome P450 
isozyme family in the liver. This leads to a reduced clearance 
of drugs such as warfarin, digoxin, simvastatin, metoprolol, 
diltiazem, flecainide, procainamide. A 30%–50% potentiation 
of the effect of warfarin,37 a doubling in serum digoxin levels,41 
and a dose-dependent risk of rhabdomyolysis with simvastatin 
doses exceeding 20 mg have been described.42
intravenous formulation
The predominant clinical adverse event associated with the 
intravenous administration of amiodarone is hypotension, 
caused by a negative inotropic effect and a decrease in 
systemic vascular resistance.43 This effect is mainly caused 
by the cosolvents, polysorbate-80 and benzyl alcohol, used 
in the currently available form of intravenous amiodarone. 
To minimize these effects the drug is diluted in 5% dex-
trose in water and slowly infused. In three controlled trials, 
hypotension was reported in 10%–30% of patients.44 It was 
observed more commonly with rapid rates of infusion, but 
no significant differences among the different dose groups 
were seen.
Depression of sinus node function and AV block can occur 
and should always be anticipated.
Thrombophlebitis has been reported in .50% of patients 
after administration of intravenous amiodarone through a 
peripheral vein.45 To avoid this side effect, administration 
through a central intravenous line is recommended.
Acute hepatitis has been reported after administration 
of intravenous amiodarone,46 but organ toxicity is rare and 
Table 1 Adverse effects during long-term amiodarone therapy
Extracardiac Cardiac
Hypothyroidism/hyperthyroidism Sinus bradycardia
Skin: sun sensitivity, skin discoloration High degree AV block
Central nervous system: tremors, ataxia, 
nightmares, parasthesiae
Torsade de Pointes
Visual disturbances
Gastrointestinal: constipation, anorexia, nausea
Abnormal liver function: abnormal 
ALT and AST levels
Pulmonary fibrosis
Reduced clearance of other drugs: eg, warfarin, 
digoxin, simvistatin, metoprolol, diltiazem, flacainide, 
procainamide Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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only noted after prolonged administration of the intravenous 
preparation.44
Alternatives
Oral formulation
Dronedarone is a derivative of amiodarone with a similar 
electropharmacologic profile, but without iodine to elimi-
nate the iodine-related adverse reactions.47 The ATHENA 
(A placebo-controlled, double-blind, parallel arm Trial to 
assess the efficacy of dronedarone 400 mg bid for the pre-
vention of cardiovascular Hospitalization or death from any 
cause in patiENts with Atrial fibrillation/atrial flutter) study, 
showed fewer cardiovascular hospitalizations or deaths 
when treated with dronedarone, compared to placebo.47 
On the other hand, the Antiarrhythmic Trial with Drone-
darone in Moderate to Severe CHF Evaluating Morbidity 
Decrease (ANDROMEDA) had to be halted early because 
of increased mortality in the dronedarone group.48 In this 
trial, patients who were hospitalized with symptomatic 
heart failure and severe left ventricular systolic dysfunction 
were randomized to receive 400 mg of dronedarone twice 
a day or placebo. Dronedarone has not been specifically 
tested for VT/VF.
intravenous formulation
Several practical difficulties arise when the current formula-
tion of intravenous amiodarone has to be administered in 
an emergency setting. With this formulation amiodarone 
must be aspirated from glass ampoules (due to adsorption 
on to plastics and rubber), then filtered and diluted before 
use. When agitated or aspirated too rapidly the drug may 
foam which may compromise proper dosing. The current 
formulation is also incompatible with electrolyte solutions 
other than dextrose in water. Furthermore, the cosolvents 
are presumably largely responsible for the adverse effect of 
hypotension.43
These practical considerations may cause a consider-
able delay in drug administration and prevent bolus push of 
the drug. Since rapid drug administration has been proven 
important, efforts have been focused on the development of 
alternative formulations of amiodarone, including an emul-
sion with tocopherol,49 a suspension of amiodarone in 0.1 
M acetate buffer at pH 3.8,50 a suspension of amiodarone 
in lactate buffer,51 amiodarone solubilized in methoxy poly 
(ethylene oxide)-block-poly(ester) micelles52 and amio-
darone solubilized in sulfobutylether-7-beta-cyclodextrin 
(Captisol®).53 In December 2008 this latter formulation, 
branded Nexterone®, was approved by the FDA, with the 
same label indications as the previously approved formulation 
of amiodarone. The diluent, Captisol®, is an FDA approved 
excipient, which is hemodynamically and electrophysiologi-
cally inert, and well-tolerated with no known organ toxicity in 
humans.54 This formulation of amiodarone is compatible with 
ionic solutions besides dextrose in water, does not adsorb to 
plastics, and can be packaged in pre-filled syringes that may 
be administered as an intravenous push immediately after 
establishing IV access. Administration of captisol-enabled 
amiodarone as a rapid IV bolus (150 mg) and as an infusion 
is bioequivalent to the approved formulation of amiodarone, 
with identical electrophysiologic effects after bolus dosing. 
Hypotensive effects have not been observed after 150 mg 
bolus intravenous administration.53,55
Summary
Despite the well-understood toxicity of amiodarone, it 
remains the most effective and safe, in the short term, 
antiarrhythmic drug for ventricular arrhythmias. It can be 
considered as first line therapy in patients with hemody-
namically significant ventricular tachycardia, particularly 
if recurrent. In patients with an ICD, it can be used as 
adjunctive therapy to prevent VT or VF recurrences, 
especially in patients with frequent events or those with 
electrical storm.
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